• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


CyPass Micro Stent New Enrollment PAS

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number P150037 / PAS002
Date Current Protocol Accepted 08/18/2017
Study Name CyPass Micro Stent New Enrollment PAS
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Objective Performance Criterion
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description To demonstrate that the rate of clinically relevant complications associated with CyPass Micro-Stent placement and stability using the CyPass 241-S applier, as determined at 36 months in the postmarket setting, is less than the pre- specified performance target, which is based on experience with the CyPass Model E applier in the COMPASS (TMI-09-01) Trial.

This is a prospective, non-randomized, multicenter, single arm, post approval study of the CyPass System. This is a new enrollment study that is expected to last up to 37.5 months and include 10 study visits.
Study Population Description Adults who must have Primary Open Angle Glaucoma (POAG) in the study eye and also be undergoing cataract surgery in that eye. No comparator group.

Inclusion criteria:
1. Adults, 45 years of age or older at the time of surgery
2. Able to understand the requirements of the study and willing to follow study instructions, provide written informed consent, and agree to comply with all study requirements, including the required study follow-up visits
3. Diagnosis of primary open angle glaucoma (POAG) substantiated using funduscopic exam and at least one reliable visual field test with the Humphrey automated perimeter using the SITA Standard 24-2 testing algorithm. Mean deviation score must be greater than or equal to-12.0 dB and less than 0 dB. The visual field test may be historical (up to 6 months prior to screening – Visit 0). If needed, visual field testing may be repeated between screening (Visit 0) and surgery (Visit 00). NOTE: A reliable visual field test is defined as one in which fixation losses (FL) are less than or equal to 20% and the false positive (FP) response rate is less than or equal to 15% (Rao 2015).
4. Medicated intraocular pressure (IOP) of greater than or equal to 10 mmHg and less than or equal to 25
mmHg, or an unmedicated IOP of greater than or equal to 21 mmHg and less than or equal to 33 mmHg
5. Gonioscopy confirming normal angle anatomy
6. Shaffer grade of greater than or equal to III in all four quadrants
7. An operable age-related cataract with best corrected distance visual acuity (BCDVA) of 0.3 logMAR or worse (less than or equal to 85 letters read), eligible for phacoemulsification. If the BCDVA is better than 0.3 logMAR (greater than 85 letters read), testing with a Brightness Acuity Meter (BAT) on a medium setting must result in a BCDVA of 0.3 logMAR or worse (less than or equal to 85 letters read).
8. An intact and centered capsulorhexis or capsulotomy
9. An intact posterior capsular bag
10. A well-centered IOL implant placed in the capsular bag
11. A clear view of an open angle and visualization of the angle with direct gonioscopy post intracameral miotic instillation
12. No evidence of zonular dehiscence/rupture (uncomplicated cataract extraction)
Sample Size 640 subjects will be enrolled, 360 eyes of 360 subjects (limit one eye per subject) will complete the study and provide 36- month data for statistical analyses at approximately 20 sites (approximately 22 subjects implanted per site).
Data Collection Primary Effectiveness Endpoints: None.
Secondary Effectiveness Endpoints:
All secondary effectiveness endpoints will be evaluated at 36 months postoperatively.
Mean change in IOP
Proportion of subjects with IOP reduction greater than or equal to 20% while using the same or fewer topical ocular hypotensive medications
Proportion of subjects who are not using ocular hypotensive medication with IOP greater than or equal to 6mmHg and less than or equal to 18 mmHg
Primary Safety Endpoints:
The rate of clinically relevant complications associated with CyPass Micro-Stent placement and stability as determined at 36 months. Specific device-related complications include:
Failure to implant CyPass, defined as inability to successfully deploy or insert the CyPass.
Clinically significant CyPass malposition, defined as CyPass positioning after deployment such that:
The device is not in the supraciliary space, or
There is a clinical sequela resulting from device position including, but not limited to:
Secondary surgical intervention to modify device position (eg, repositioning, proximal end trimming or explantation)
Corneal endothelial touch by device
Corneal edema leading to loss of BCDVA > 2 lines at the last postoperative visit, in comparison with preoperative BCDVA
Progressive endothelial cell loss (ECL), defined as ongoing reduction in endothelial cell count of 30% or more relative to the screening endothelial cell density (ECD) value
Erosion of device through sclera
Device obstruction requiring secondary surgical intervention.
Secondary Safety Endpoints:
All secondary safety endpoints will be evaluated at 36 months postoperatively.
Rate of occurrence of sight-threatening adverse events including
Persistent (at time of study exit) BCDVA loss of 3 or more lines compared to best BCDVA achieved during the course of study
Corneal decompensation
Retinal detachment
Severe choroidal hemorrhage or detachment o Aqueous misdirection
The rate of ocular secondary surgical interventions (SSI)
The rate of ocular SSIs associated with CyPass placement and stability
Other Safety Endpoints:
All other safety endpoints will be evaluated at 36 months postoperatively.
Increase from baseline IOP of 10 mmHg or greater at any time at/after 30 days postoperative
BCDVA loss of 2 or more lines compared to screening (Visit 0)
BCDVA loss of 2 or more lines in comparison with best recorded BCDVA at any postoperative visit
Device movement, defined as a change by at least 1 in the number of CyPass rings visible (e.g., from 1 ring to 2 rings or from 3 rings to 2 rings) that does not result in clinical sequelae (e.g., secondary surgical intervention to modify device position, corneal endothelial touch by device, corneal edema leading to loss of BCDVA > 2 lines at the last postoperative visit in comparison with preoperative BCDVA, progressive endothelial cell loss, erosion of device through sclera, or device obstruction requiring secondary surgical intervention), and that is not attributable to any one or
more of the following:
variations in gonioscopic viewing angle or illumination
changes in angle anatomy due to concomitant findings such as resolution of hyphema
changes in anterior chamber depth
development of focal peripheral anterior synechiae

Follow-up Visits and Length of Follow-up 36 months
Interim or Final Data Summary
Interim Safety Information As of June 3, 2021, 1 patient is reported with device malposition with device implantation in the choroidal space rather than the supraciliary space. There are two adverse events requiring secondary surgical intervention; both events were reported as elevated intraocular pressure treated with paracentesis. Two patients have reported device dislodgement or movement without sequelae (OD). No patients are reported with endothelial cell density (ECD) < 1000 cells/mm2. At the 24-month evaluation the mean endothelial cell loss (ECL) was 18% with a median of 17%. At 24-months in the PMA study, the mean ECL was 13% with a median value of 10%. The percentage of subjects at 24 months with > 30% ECL is reported as 22.2% in this PAS compared to 11.2% in the PMA study. A reported 28% (12/43) of the patients in this PAS had greater than 1 ring visible at the time of surgery, and in 12% (5/43) of the patients, 0 or 1 ring was reported at the time of surgery, but the number of visible rings was greater at later reporting periods.
All secondary effectiveness endpoints will be evaluated at 36 months postoperatively.
Actual Number of Patients Enrolled 79 enrolled; 43 patients received the implant. Enrollment was halted after the device was removed from the market in August 2018
Actual Number of Sites Enrolled 24

Patient Follow-up Rate 3-month visit: 100%
6-month visit: 92.9%
12-month visit: 97.6%
24-month visit: 84.6%
36-month visit: 92.3%
Study Strengths & Weaknesses The study enrollment was stopped prematurely due to market withdrawal; however, the enrolled patients who were previously implanted continue to be actively followed.

CyPass Micro Stent New Enrollment PAS Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
six month report 01/27/2017 01/25/2017 On Time
one year report 07/29/2017 07/25/2017 On Time
18 month report 01/27/2018 01/26/2018 On Time
two year report 07/29/2018 07/25/2018 On Time
three year report 07/29/2019 07/25/2019 On Time
four year report 07/28/2020 07/24/2020 On Time
five year report 07/28/2021 07/27/2021 On Time
final report 07/20/2023 03/11/2022 On Time

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources